Metabolic & Cardiometabolic
statins worsens skeletal-muscle mitochondrial function and CoQ10 status, contributing to myalgia
In plain terms: Do statins damage muscle energy machinery (mitochondria/CoQ10) and cause the muscle aches people report?
Part of: 💊 statins
Statins measurably lower muscle mitochondrial respiration, but CoQ10 depletion is inconsistent and blinded trials show most reported muscle aches are not actually caused by the drug.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
<!-- vault-context --> Norwitz affirms this claim. Consensus below reflects independent literature only.
The evidence (15)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Hussain A 2023 · Cureus | mechanism | supports | low | Narrative review states impairment of mitochondrial function is a recognized adverse effect of statins that can lead to hepatic dysfunction, neurocognitive effects, and new-onset diabetes, alongside myotoxicity/statin-associated muscle symp |
| Wood 2020 (SAMSON) venue: N Engl J Med · N Engl J Med | RCT | contradicts | high | N-of-1 crossover: 90% of statin-attributed symptom burden occurred equally on placebo; muscle symptoms largely nocebo, not pharmacological |
| Dohlmann 2022 · Antioxidants (Basel) | RCT | contradicts | moderate | 400mg/d CoQ10 x8wk did NOT change muscle CoQ10, mitochondrial function, or myalgia in statin users; argues against CoQ10-depletion mechanism for symptoms |
| Herrett 2021 (StatinWISE) venue: Health Technol Assess · Health Technol Assess | RCT | contradicts | high | 200 N-of-1 RCTs: no overall difference in muscle symptoms between atorvastatin and placebo; statins did not cause excess myalgia |
| CTT Collaboration 2022 · Lancet | meta-analysis | mixed | high | IPD of blinded RCTs: real but small excess of muscle pain/weakness (~11 events/1000 person-yr, RR 1.03 first year); >90% of reported symptoms not statin-caused |
| Mollazadeh 2021 · J Cachexia Sarcopenia Muscle | mechanism | supports | low | Mechanistic review documents statin effects lowering CoQ10, inhibiting respiratory-chain complexes and triggering mitochondrial apoptosis in muscle. |
| Asping/LIFESTAT 2017 · Eur J Clin Pharmacol | RCT | mixed | moderate | 2 weeks statin: mitochondrial respiratory capacity not significantly reduced short-term; effect emerges with longer exposure, dose/time dependent |
| Dohlmann TL et al] # corrected 2026-08-17 from PubMed; was [Mortensen/Larsen 2019 (LIFESTAT) venue: J Clin Endocrinol Metab · J Clin Endocrinol Metab | RCT | mixed | moderate | Statin decreased muscle mitochondrial respiration BUT muscle CoQ10 levels were UNALTERED, dissociating the respiration effect from CoQ10 depletion |
| El-Ganainy 2016 · Toxicology | animal | supports | low | In rats atorvastatin caused mitochondrial swelling, ATP depletion and myopathy that CoQ10 co-treatment reversed, supporting a mitochondrial mechanism. |
| Kovacic et al. 2025 · J Nutr Sci | meta-analysis | mixed | low | 7 RCTs n=389: modest overall reduction in SAMS pain with CoQ10 (WMD -0.96) but 3/7 trials null; heterogeneous, low-certainty benefit |
| Larsen 2013 · J Am Coll Cardiol | observational | supports | moderate | Simvastatin users had reduced muscle mitochondrial OXPHOS capacity and lower CoQ10 vs controls, linking statin to impaired respiration |
| Golomb BA 2023 · J Clin Med | observational | supports | low | Review argues statins impair mitochondrial function in those most reliant on CoQ10 (a mevalonate pathway product transported on cholesterol), amplifying risk in patients with existing mitochondrial compromise; argument made in context of CO |
| Peyrel 2023 · PLoS One | observational | mixed | low | In patients reporting statin muscle symptoms, drug withdrawal improved perceived but not objective muscle function, implicating a nocebo rather than true mitochondrial injury for the reported aches. |
| Braczko A 2023 · Front Physiol | in-vitro | tested-null | low | In mouse heart microvascular endothelial cells and cardiomyocytes under normal conditions, atorvastatin (unlike a PCSK9 inhibitor) did not enhance mitochondrial respiratory parameters, but under hypoxia-mimicking conditions atorvastatin act |
| Somers T 2024 · Biomed Pharmacother | observational | supports | high | In ex vivo human cardiac and skeletal muscle tissue from statin users vs controls, statins reduced fatty acid oxidation and mitochondrial complex I/II activity in cardiac muscle, and confirmed inhibition of mitochondrial complex III in skel |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.